Copper-64 (T 1/2 ¼ 12.7 hours; b þ : 19%, b À : 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems. It can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. Two potential ways to produce copper-64 radioisotopes concern the use of the cyclotron or the reactor. This review summarized several commonly used biomarkers of copper-64 radionuclide.
Introduction
As molecular imaging continues to advance, positron emission tomography (PET) and single photon emission computed tomography (SPECT) technology are nowadays an integral part of the molecular imaging toolbox. Dual-modality imaging, such as PET/computed tomography (CT) or SPECT/CT, integrates the high-resolution anatomical images with physiological information, which enables the investigators to identify the physiological basis of the disease and correlate it with the anatomical image. 1 Radioactive copper is one of the most actively studied radionuclides. [2] [3] [4] Several reasons render this element so attractive for PET imaging. The long half-life of the copper allows sufficient uptake and distribution to yield considerable contrast and quality of images. In addition, copper can react with many chelator systems due to its well-established coordination chemistry, and it can be linked to antibodies, proteins, peptides, and other biologically relevant small molecules. 5 The most extensively used class of chelators for 64 Cu has been shown in Figure 1 . Among the 27 known copper radioisotopes, 5 of them are particularly interesting for molecular imaging applications ( 60 Cu, 61 Cu, 62 Cu, and 64 Cu) and in radiotherapy ( 64 Cu and 67 Cu). 4 Table 1 lists their nuclear characteristics. Availability of Cu isotopes for preclinical and clinical research has been greatly improved in the recent years, since many potential chelators have been developed over the last decade. A number of compounds coupled with Cu have been proposed not only for PET diagnostic imaging but also for targeted radiotherapy of tumor. Table 2 lists the most popular radiopharmaceuticals that were modified to be used with 64 Cu for cancer imaging and therapy. In the present study, we aimed to systematically review several commonly used biomarkers of 64 Cu radionuclide.
Production of Cu Radioisotope
The 2 potential ways to produce Cu radioisotopes include the use of the cyclotron or the reactor. 6 Copper-64, the most commonly used copper radionuclide, is characterized by a unique decay scheme (b þ : 19%, b À : 38% and electron capture: 43%).
Such property allows either cyclotron or reactor production, and the latter route results in either low-specific activity (n, g) or high-specific activity (n, p) products. 511-467-826-1332 61 Cu 3.3 h b þ (60%) 1220,1159 g (40%)
511-283-589-656 62 Cu 9.7 min b þ (98%) 2925 g (2%) 511 64 Cu 12.7 h b þ (19%) 657 g (43%)
511-1346 b À (38%) 141 67 Cu
91-93-185 Cu-DOTA-alendronate Imaging Breast cancer 82 Szelecsenyi et al 7 proposed 64 Cu reaction on a biomedical cyclotron, and small irradiations were performed to demonstrate the feasibility of 64 Cu production by this method. At present, the most common production method for 64 Cu utilizes the 64 Ni (p, n) 64 Cu reaction, 5 which yields a large quantity of nuclides with high-specific activity. However, such method needs enriched 64 Ni leading to increased overall costs. 8 The target for producing 64 Cu is enriched 64 Ni (99.6%).
9
The 64 Ni is plated on the gold disk using a procedure modified from Piel et al. 10 At Washington University School of Medicine, 64 Cu is produced on a CS-15 cyclotron using 15.5 MeV protons (15-45 mA beam current) by the 64 Ni(p, n) 64 Cu reaction. After bombardment, the 64 Cu is separated from the target nickel in a 1-step procedure using an ion-exchange column. 9 64 Zn (n, p) 64 Cu reaction in nuclear reactor is another method for production of 64 Cu. 11 Most reactor-produced radionuclides are produced through thermal neutron reactions or (n, g) reactions. Thermal neutrons have an advantage of relatively low cost, and its target material is of the same element as the product radionuclide. Meanwhile, in order to generate 64 Cu with a high specific activity, fast neutrons are employed to bombard the target in an (n, p) reaction. Unlike a thermal neutron reaction, a fast or highly energetic neutron has sufficient energy to eject a particle from the target nucleus. 12 However, many highly radioactive by-products of the reaction need to be removed and handled properly. 64 
Cu-diacetyl-bis (N4-methylthiosemicarbazone)
Hypoxia is a pathological condition arising in living tissues when oxygen supply does not adequately cover the cellular metabolic demand. Tomlinson and Gray, for the first time, have demonstrated the presence of hypoxia in human tumors in the early 1960s, 13 and the hypoxic tissue in the tumors has certain resistance to traditional radiotherapy and chemotherapy, leading to increased aggressiveness, metastatic spread, enhanced rate of recurrence, and ultimately poor outcomes.
14 Therefore, an important relationship exists between the assessment of tumor hypoxia and prognosis. Hypoxic regions can be visualized by combination of PET and oxygen-dependent cellular uptake of radiopharmaceuticals. In recent years, Cu-diacetylbis (N4-methylthiosemicarbazone) (Cu-ATSM) labeled with a positron-emitting isotope of copper, such as 60 Cu, 62 Cu and 64 Cu, has been developed as an imaging agent targeting the hypoxic regions in tumors for use with PET. [15] [16] [17] [18] [19] [20] Cu-ATSM has high membrane permeability and low redox potential, and it can passively diffuse within the intracellular environment to maintain the stability of normal tissue.
Mechanisms underlying the selective uptake of 64 Cu-ATSM in hypoxic areas still remain largely unexplored. Fujibayashi et al 21 suggested that Cu(II)-ATSM reduction occurs only in hypoxic cells due to the abnormally reduced state of their mitochondria and does not occur in normoxic cells. With extensive research on 64 Cu-ATSM, another mechanism is that Cu(II)-ATSM is reduced by thiols and converted into Cu(I)-ATSM complex both in normal and in hypoxic cells. 22 In normal cells, 64 Cu(I)-ATSM is again oxidized to 64 Cu(II)-ATSM and then freely diffused out of the cells. 23 Under hypoxic conditions, this complex is less stable than its bivalent form and progressively dissociated into H 2 -ATSM and free Cu(I), which are then rapidly entrapped in intracellular proteins. 21 McCall et al 15 assessed the role of 64 Cu-ATSM in head and neck squamous cell carcinoma (HNSCC) xenograft model through a combination of in vivo PET imaging and in vitro autoradiography and founded that the uptake of 64 Cu-ATSM in tumors was significantly higher than that in muscles. The PET image showed large tumor-to-muscle ratios, which were continually increased over an 18-hour period of imaging after injection. The results indicated that 64 Cu-ATSM uptake was specific for malignant expression. A prospective study 16 assessed the prognostic significance of 64 Cu-ATSM in 18 patients with locally advanced non-small cell lung cancer (NSCLC; n ¼ 7) or head and neck cancer (HNC; n ¼ 11) before treatment. Semi-quantitative and quantitative parameters on PET were calculated, including standardized uptake value (SUV) max , SUV ratio-to muscle , SUV mean , hypoxic tumor volume (HTV), and hypoxic burden (HB ¼ HTV Â SUV mean ). These data were subsequently correlated to disease outcomes, which were expressed in terms of progression-free survival calculated on a follow-up period with a median of 14.6 months. These analyses demonstrated that volumetric parameters were the most robust predictors of outcome, and patients with lower HTV and HB tend to have a better prognosis. Another prospective study 17 also assessed the prognostic role of 64 Cu-ATSM PET/CT pretreatment in 11 patients with HNC (III-IV). No significant difference was found in SUV max between early (1 hour post injection) and late (16 hours post injection) acquisitions. Moreover, 64 Cu-ATSM showed high sensitivity (true positive rate, the percentage of positives that are correctly identified; 100%) but low specificity (true negative rate, the percentage of negatives that are correctly identified) in predicting therapy response based on both SUV max and HTV, which can be probably attributed to the presence of undetectable hypoxia with the current method. Besides, 18F-fluorodeoxyglucose ( 18 F-FDG) and 64 Cu-ATSM provide similar results about delineation of biological tumor volume.
Several studies were conducted using 60 Cu in cervical cancer, and similar results in predicting the tumor response to therapy were obtained. 18 In fact, the pattern and magnitude of tumor uptake of 60 Cu and 64 Cu-ATSM are similar even if image quality is better in 64 Cu than in 60 Cu. 19 Therefore, 64 Cu-ATSM may be a predictive indicator of tumor response to therapy in patients with cervical cancer.
In 9 gliosarcoma rat models, 20 64 Cu-ATSM uptake was measured in tumor tissue under different oxygen partial pressures (pO 2 ), and there was a good correlation between low pO 2 and high 64 Cu-ATSM accumulation. The uptake of 64 Cu-ATSM in tissues in vivo depends on the tissue pO 2 , and significantly greater uptake and retention occur in hypoxic tumor tissue.
Since radiation resistance of hypoxic tumor is a well-known phenomenon, it is very important to assess the extent and location of hypoxia within a tumor. As a hypoxia imaging agent with high tumor-to-background ratios, 64 Cu-ATSM allows targeting of positive lesions with high sensitivity and specificity on PET. Hypoxia imaging-guided intensity-modulated radiation therapy can deliver higher dose of radiation to the hypoxic tumor and normal tissues.
However, some preclinical data suggested that 64 Cu-ATSM was not a hypoxia marker in all types of tumor. Vāvere et al 24 found that the relationship between 64 Cu-ATSM and overexpression of fatty acid synthase (FAS) was associated with prostate cancer (PCa), and the physiological significance of the FAS pathway in PCa was the harnessing of its oxidizing power for improving redox balance (ie, lower NADH/NAD þ ratios), despite under oxygen-limiting (hypoxic) conditions causing low 64 Cu-ATSM uptake in hypoxic and normoxic regions. Therefore, the translation of 64 Cu-ATSM to imaging of PCa may be limited by the overexpression of FAS associated with prostatic malignancies. 64 Cu is not only useful for PET imaging but also has potential as an agent for internal radiotherapy, since its favorable b À decay (38%) and Auger electrons emitted from this nuclide can damage tumor cells. 25, 26 Yukie et al 26 studied the therapeutic effect of 64 Cu-ATSM in HT-29 tumor-bearing mice after treating with bevacizumab, and the results showed that 64 Cu-ATSM effectively inhibited the growth of HT-29 tumors, exhibiting bevacizumab-induced vascular decrease and hypoxia. Therefore, it prolongs the survival of mice during bevacizumab treatment with negligible toxic side effects. Jason et al 25 also found that 64 Cu-ATSM significantly increased the survival time of hamsters bearing human GW39 colon cancer tumors. Yoshii et al 27 showed that the 64 Cu-ATSM uptake region of tumors was associated with upregulation of DNA repair and a high ratio of CD133 þ cells. CD133 þ cells have been reported to be highly resistant to conventional radiotherapy and chemotherapy in many types of cancer. 64 Cu-ATSM decreased the number of CD133 þ cells not via specific interactions, but it was accumulated in CD133 þ cell-rich regions within tumor, leading to higher doses of radiation in those areas. 28 64 CuCl 2 64 CuCl 2 , as the substrate of CTR1, has been demonstrated as a promising PET tracer for imaging animal models with tumors, such as melanoma, glioblastoma multiform, and PCa. [29] [30] [31] More importantly, some studies have shown that 64 CuCl 2 -PET/CT is used in human study. 30, 32 Peng et al 31 found that human PCa xenografts may be localized by PET using 64 CuCl 2 as a probe. Piccardo et al 33 prospectively evaluated 50 patients with PCa and showed that 64 CuCl 2 PET/CT possessed a significantly higher detection rate than 18 F-choline PET-CT. Jiang et al 34 studied animal models of H 2 O 2 -induced muscle inflammation and lipopolysaccharide-induced lung inflammation and revealed that the inflammatory muscles and lungs had a significantly higher 64 Cu accumulation than their corresponding controls (P < .05). The potential diagnostic role of 64 CuCl 2 PET/CT imaging for brain malignancies has been recently evaluated in 19 patients with a documented history and radiologic evidence of cerebral tumors. 30 After initial cerebral magnetic resonance imaging (MRI), patients were administered with 64 CuCl 2 (13 MBq/kg), and brain PET/CT imaging was performed at 1, 3, and 24 hours after administration. Excellent agreement was found between PET/CT and MRI. Brain cancerous lesions can be clearly visualized within 1 hour after injection of 64 CuCl 2 , with stable retention of radioactivity up to 24 hours. The radioactivity was cleared rapidly from the blood and mostly excreted through the liver. The major limitation of this study was that only a small number of patients were enrolled. However, these preliminary clinical data suggested that 64 CuCl 2 can be a potentially useful diagnostic agent for malignancies of the central nervous system (CNS). 64 
Cu-Labeled Antibodies for Tumor Targeting
As a large class of biotechnologically created proteins, monoclonal antibodies (mAbs) have been increasingly used in immunotherapy, targeted drug delivery, and in vivo/in vitro diagnostics. Trastuzumab (breast cancer expressing human epidermal growth factor receptor [EGFR] 2 or human epidermal growth factor receptor [HER2]), cetuximab (targeting EGFRexpressing tumors), TRC105-Fab (targeting CD105), and etaracizumab (antibody against human a n b 3 integrin) are the main monoclonal antibodies for 64 Cu labeling for PET imaging. 2 
64
Cu-trastuzumab HER2 status in breast cancer determines its therapeutic strategy. 35 Humanized anti-HER2 antibody trastuzumab is a wellestablished therapeutic strategy for HER2-positive breast cancer in neoadjuvant, adjuvant, and metastatic settings, and it increases overall survival for patients with HER2-positive breast cancer. 36 Several reports showed that 64 Cu-DOTAtrastuzumab PET imaging can be used to visualize primary and metastatic HER2-positive lesions [35] [36] [37] [38] and better identify patients who may benefit from these expensive and potentially toxic treatments through a noninvasive approach.
Sasada et al 35 evaluated the concordance of HER2 expression in primary breast tumors between HER2-PET imaging and immunohistochemistry (IHC) in 38 patients with breast cancer. Significant difference in mean SUV max value was found between HER2-positive and HER2-negative breast tumors, and SUV max values were correlated with HER2-IHC scores (correlation coefficient ¼ .619). When the cutoff value of SUV max by HER2-PET imaging was set at 1.98, the sensitivity, specificity, and accuracy (the correctly identified fraction among the whole instances) were 83.3%, 88.2%, and 85.7%, respectively. Another study evaluated the feasibility and potential utility of 64 Cu-DOTA-trastuzumab PET/CT for lesion detection and uptake measurement in 6 patients with HER2-positive metastatic breast cancer. 37 After initial 18 F-FDG PET/CT, patients were administered with 45 mg 64 Cu-DOTA-trastuzumab, and PET/CT imaging was performed 21 to 25 (day 1) and 47 to 49 (day 2) hours after injection of 64 Cu-DOTA-trastuzumab. The results showed that 64 Cu-DOTA-trastuzumab was rapidly accumulated in tumors after 1 hour of injection, and the detection sensitivity on day 1 and day 2 were 77% and 89%, respectively. Besides, no unanticipated toxicities or adverse side effects were observed in these 6 patients. The authors concluded that 64 Cu-DOTA-trastuzumab PET/CT was a practically and acceptably safe procedure in patients with metastatic breast cancer. A preliminary clinical study suggested that HER2-specific 64 Cu-DOTA-trastuzumab also accumulated in brain metastasis as evidenced by autoradiography, IHC, and liquid chromatography-tandem mass spectrometry. 38 
Cu-cetuximab
EGFR is a member of the erbB family of tyrosine kinase receptors, 39 and the dysregulation of EGFR leads to several key features of cancer, such as autonomous cell growth, apoptosis and inhibition of angiogenesis, invasion, and metastases. 40 However, many studies have found that EGFR is overexpressed in many human tumors, including HNSCC, colon cancer, NSCLC, and cervical cancer. 41, 42 Cetuximab with high affinity to EGFR, which was the first mAb against the EGFR or the treatment of patients with EGFR-expressing metastatic colorectal carcinoma approved by the US Food and Drug Administration. 5 In recent decades, radio-labeled anti-EGFR antibodies, such as 64 Cu-cetuximab, were studied for diagnosis, monitoring, and efficacy evaluation of EGFRexpressing tumors.
Cai et al, 42 for the first time, evaluated the quantitative PET imaging of EGFR expression in xenograft-bearing mice using 64 Cu-labeled cetuximab. In this study, 7 different types of cancer cell lines (U87MG human glioblastoma, PC-3 human prostate carcinoma, CT-26 murine colorectal carcinoma, HCT-8, HCT-116, and SW620 human colorectal carcinoma, and MDA-MB-435 human breast cancer) were selected, and a good correlation (R 2 ¼ .80) between the tracer uptake (measured by PET) and the EGFR expression (measured by Western blotting) was confirmed. As expected, 64 Cu-DOTA-cetuximab showed significantly increased accumulation of tumor activity over time in EGFR-positive tumors (U87MG and PC-3 tumors), but it had relatively low uptake in EGFR-negative tumors (<5% ID/g). The radioactivity was mainly cleared through the hepatic pathway, and virtually no renal uptake or renal clearance was observed. The results of this study further revealed the potential utility of cetuximab for tumor diagnosis using PET as well as for determining patient-specific therapies and therapeutic efficacy monitoring.
In another interesting study, Laura et al 43 developed and characterized an EGFR-directed PET tracer, 64 Cu-cetuximab-F(ab 0 )2, to determine the systemic accessibility of EGFR. The authors selected male mice bearing human HNSCC xenografts UT-squamous cell carcinoma (SCC-8; n ¼ 6) or UT-SCC-45 (n ¼ 6). After 1 mouse for each tumor model was injected with excess unlabeled cetuximab (1 mg) for 3 days, 64 Cu-cetuximab-F(ab 0 )2 (21 + 2.6 MBq,15 mg, 250 mL) PET/CT imaging was performed for UT-SCC-8and UT-SCC-45 mice. In vivo PET imaging and biodistribution studies demonstrated significant tumor uptake with good tumor-to-background signal at 24 hours after injection. The results indicated that 64 Cu-cetuximab-F(ab 0 )2 uptake was correlated with EGFR expression in both tumors, and UT-SCC-8 had a significantly higher expression of EGFR compared to UT-SCC-45. The preclinical data indicated the potential of 64 Cu-cetuximab-F(ab 0 )2 as a clinical EGFR-targeting tracer. 64 
Cu-TRC105-Fab
Tumor cells rely on newly formed tumor vessels for adequate nutrition during tumor growth, without which they cannot grow beyond a critical size or metastasize to another organ. 44 In the past 2 decades, efforts were made to find specific markers for newly formed tumor angiogenesis, and many targets have been widely studied for noninvasive imaging of tumor angiogenesis. 45, 46 CD105 is mainly overexpressed on proliferating endothelial cells, and it is a promising candidate for tumor vascular targeting. High CD105 intratumor microvessel density is correlated with lower patient survival rates in multiple solid cancers, such as breast cancer, gastrointestinal, cancer, and PCa. 47 As an accepted standard approach to identify actively proliferating tumor vessels, CD105 IHC has several potential advantages over the other targets, including overexpression in many solid malignancies, effective evaluation of the efficacy of antiangiogenic treatments, independence of its expression on neoplastic cells, lack of tumor histotype specificity, and immediate accessibility of malignant lesions through the blood stream. 5 With good affinity and specificity for CD105 on the tumor vasculature, radiolabeled TRC105-Fab can be potentially used as a promising imaging and diagnostic vascular agent for PET imaging in human tumors. 45 Yin et al 45 reported PET imaging of CD105 expression in 4T1 murine model of breast cancer using 61/64 Cu-NOTA-TRC105-Fab, exhibiting prominent and target-specific uptake in the 4T1 tumor. Besides, the use of a Fab fragment leads to much faster tumor uptake (which peaks at a few hours after tracer injection) compared to radio-labeled intact antibody, which may be translated into same-day immune-PET imaging for clinical investigation. 64 
Cu-Integrin-Targeting Peptides
As a transmembrane glycoprotein receptor and an important cell adhesion molecule, alpha n beta 3 (a n b 3 ) plays important roles in tumor growth, invasion, metastasis, and angiogenesis. 48 It is highly expressed on various types of tumor cells, including glioblastomas, breast cancer, PCa, malignant melanomas, and ovarian carcinomas. 5 The cyclic pentapeptide containing a tripeptide sequence Arg-Gly-Asp (cRGD) has been identified with high specificity and affinity for the a n b 3 . 48 Sprague et al 49 evaluated 64 Cu-labeled c(RGDyK) peptides conjugated to a different chelator, CB-TE2A, and found that the corresponding 64 Cu complex was taken up specifically by osteoclasts, which were upregulated in osteolytic lesions and bone metastases. Ocak et al 50 compared 64 Cu-labeled c(RGDyK) peptides with previously reported CB-TE2A conjugates of c(RGDyK) for imaging osteoclasts in the 4T1 mouse, a mammary tumor model of bone metastases. This study demonstrated that although all chelator-peptide conjugates showed similar binding affinity for integrin a n b 3 , the in vivo tumor targeting of CB-TE1A1P was superior to CB-TE2A-c(RGDyK). There is also improved kidney function and liver clearance for 64 Cu-TE1A1P-DBCOc(RGDyK). In addition, PET imaging with 64 Cu-labeled c(RGDyK) can be informative for diagnosis and/or monitoring treatment for other diseases with high levels of osteoclasts, such asosteoarthritis. 51 ,52 64 
Cu-Somatostatin Analogues
Somatostatin (SST) receptors (SSTRs) are G-protein-coupled receptors expressed on cell membranes, and 5 subtypes of SSTRs (SSTRl to SSTR5) have been identified to date. 53 The SSTRs are highly expressed in neuroendocrine tumors (NETs), such as pheochromocytoma, pituitary adenoma, carcinoid tumor, and medullary thyroid carcinoma, but they are also positive on the cell surfaces of other non-neurocytic tumor cells, including gliomas, meningioma, small cell lung cancer, and neuroblastoma. 54 SST and its analogues bind to SSTRs with high affinity and high specificity, inactivate the signal transcription, and suppress the growth of corresponding tissue cells, thereby inhibiting the growth of tumor cells. 55 An 8-amino acid analog of SST, octreotide (OC), possesses a longer biologic half-life, and it is much more effective in inhibiting the secretion of growth hormone compared to SST.
14 Several radiotracers containing an SST analog chelated to a radioisotope were developed for SSTR imaging.
Anderson et al 56 demonstrated that 64 Cu-TETA-OC can be used to detect SSTR-positive tumors in humans. 64 Cu-TETA-OC PET shows higher rate of lesion detection, good sensitivity, favorable dosimetry, and pharmacokinetics for NET imaging compared to 111 In-DTPA-OC SPECT, partially due to the greater sensitivity of PET. Pfeifer et al 57 prospectively studied 112 patients with pathologically confirmed NETs of gastroenteropancreatic or pulmonary origin and found that the diagnostic sensitivity, accuracy, and negative predictive value (NPV; the fraction of correctly identified as negatives among the whole instances that were identified as negatives) of 64 Cu-DOTA-TATE were higher than those of 111 In-DTPA-OC (97%, 97%, and 80% vs 87%, 88%, and 48%, respectively). Results showed that the diagnostic value of 64 Cu-DOTA-TATE in patients with NETs was significantly better than that of 111 In-DTPA-OC. Therefore, 64 Cu-TETA-OC can replace 111 In-DTPA-OC in diagnosis of NETs. A similar head-tohead comparison was conducted to assess the diagnostic value of 64 Cu-DOTA-TATE and 68 Ga-DOTA-TOC in 59 patients with NETs. 58 In the 68 inconsistent imaging areas, 64 Cu-DOTA-TATE showed 42 sites, of which 33 were found to be true positive (correctly identified instances) on follow-up. Moreover, 26 sites were detected by 68 Ga-DOTA-TOC, of which 7 were confirmed to be true-positive during follow-up. 64 Cu-DOTA-TATE finds an additional 83% of the truepositive sites, and the results showed that 64 Cu-DOTA-TATE had advantages over 68 Ga-DOTATOC in the detection of lesions in patients with NETs. In addition, 64 Cu-DOTA-TATE has a shelf life of more than 24 hours and a scanning window of at least 3 hours, making it advantageous and easy to use in a clinical setting.
Unfortunately, it was reported that Cu-TETA chelates were instable in vivo, since 64 Cu may dissociate from the TETA chelator and bind to proteins, primarily superoxide dismutase (SOD). 58 Using metabolism studies, Bass et al demonstrated that when 64 Cu-TETA-OC was injected into normal SpragueDawley rats, approximately 69% of the 64 Cu dissociates from 64 Cu-TETA-OC and binds to the protein SOD in the liver. 59 Clinical PET studies using 64 Cu-TETA-OC also resulted in retention of 64 Cu-TETA-OC in the blood and poor liver clearance in patients. 56 In another biodistribution study, 54 similar results were observed that 64 Cu-DOTA-TOC had a lower stability, showing slower blood clearance and high accumulation in the liver and intestine. Sun et al 60 evaluated the radiochemistry and biodistribution of 4 64 Cu-labeled cross-bridged cyclam ligands and found that 64 Cu-CB-TE2A (CB-TC2A-4, 11-bis (carboxymethyl)-1, 4, 8, 11-tetraazabicycl[6.6.2] hexadecane) had the most rapid clearance through blood, liver, and kidney compared to 64 Cu-TETA. Sarkar et al 61 investigated the biophysical and chemical properties of 5 closely related bifunctional chelators and showed that significant differences in tissue uptake and clearance patterns were dependent on the chelator utilized in the peptide conjugate. Conjugates containing propylene cross-bridged chelators show higher tumor uptake and ultrahigh in vivo stability, while a closely related ethylene cross-bridged analogue exhibits rapid body clearance.
Malmberg et al, 62 for the first time, compared the large arterial uptake of 68 Ga-DOTA-TOC and 64 Cu-DOTA-TATE in 60 patients with NETs. The results showed that the uptake of 64 Cu-DOTA-TATE was significantly higher compared to 68 Ga-DOTA-TOC in the vascular regions. Besides, the uptake of 64 Cu-DOTA-TATE, but not 68 Ga-DOTA-TOC, was correlated with cardiovascular risk factors, suggesting a potential role for 64 Cu-DOTA-TATE in the assessment of atherosclerosis even in the subclinical stages. 64 
Cu-AE105
Extensive amount of studies implicated that the serine protease urokinase-type plasminogen activator (uPA) and its receptor (uPAR) were strongly prognostic in cancer invasion and metastasis. 63, 64 In line with this finding, several studies reported that uPAR was associated with poor prognosis and metastatic disease in various tumors, such as breast, 65 lung, 66 colorectal, 67 PCa, 68 and bladder 69 cancers. 64 Cu-DOTA-AE105 is a promising uPAR-PET ligand in several preclinical validation studies on PET imaging due to the high affinity of peptide antagonist AE105. 70 The first in-human use of 64 Cu-DOTA-AE105 dates back to 2013, when Persson et al 71 evaluated the safety, pharmacokinetics, and dosimetry of a single-dose injection of 64 Cu-DOTA-AE105 in cancer patients by serial PET-CT imaging. 64 Cu-DOTA-AE105 was well tolerated, and no adverse or clinically detectable side effects were found. The effective radiation dose was found to be 0.0276 mSv/MBq, and the liver was the organ with the highest absorption, followed by kidneys. In addition, high uptake in both primary tumor lesions and lymph node (LN) metastases were seen and paralleled by high uPAR expression in excised tumor tissue. The study concluded that uPAR-PET imaging seemed to be a highly promising technology with strong prognostic factor in patients with cancer. However, large controlled clinical trials have further indicated that these results are highly necessary. 64 
Cu-Prostate-Specific Membrane Antigen Ligand 617
Prostate-specific membrane antigen (PSMA) is a unique cell membrane surface protein, 72 which is overexpressed in PCa cells, particularly in advanced and metastatic disease, but its expression is limited in normal tissues. Low-molecular-weight radioligands have a relatively short cycle time and can be rapidly cleared from the target tissues. 73 Recently, 2-[3-(1-carboxy-5-{3-naphthalen-2-yl-2-[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraazacyclododec-1-yl) acetylamino]methyl} cyclohexanecarbonyl) amino] propionylamino} pentyl) ureido]-pentanedioic acid (PSMA-617) has been developed as a novel PSMA ligand. 68 Ga-PSMA PET/CT has a higher sensitivity than other radionuclides ( 18 F) in the detection of PCa. 74 However, due to the short half-life of 68 Ga, its application is limited to clinical PET centers with radiochemistry facility and a 68 Ga generator available on site, and a limited accuracy is found in detecting small lesions and LNs with diameters <6 mm. 75 Recently, studies were conducted using the 64 Cu alternative 68 Ga label PSMA. Radionuclides with a longer half-life, such as 64 Cu (T 1/2 ¼ 12.7 hours), allow sufficient time to clear nonspecific radioactivity in the background tissue, resulting in high tumor-to-organ ratios. 76 In addition, 64 Cu emits lower positron energy than 68 Ga, and therefore it has better image resolution. The first in-human use of 64 Cu-labeled ligand PSMA-617 for PET imaging in PCa occurs at 2 different centers in Austria and Germany. 77 In this study, the advantages of a small PSMAtargeting agent and a long-lived positron emitter with good image quality were combined, and 64 Cu-PSMA-617 resulted in high image contrast. All cases with histologically proven local diseases (23 of 29 patients) were clearly identified by 64 Cu-PSMA-617 PET. Lesions suspicious for PCa were detected with excellent contrast as early as 1 hour post-injection, with high detection rates even at low prostate-specific antigen (PSA) levels. This study showed that 64 Cu-PSMA-617 PET/CT imaging had a high potential in the detection of PCa. Cantiello et al 78 assessed the diagnostic accuracy of 64 Cu-PSMA-617 PET/CT in the primary LN staging of 23 patients with intermediate-to high-risk PCa. The final pathological results were used as reference standards. The results displayed that 64 Cu-PSMA PET/CT was always positive on PCa, and SUV max at 4 hours were significantly increased compared to that at 5 minutes and 1 hour in PCa and in LN metastases. The sensitivity, specificity, PPV (positive predictive value, the fraction of correctly identified as positives among the whole instances that were identified as positives), and NPV for LN staging of 64 Cu-PSMA PET/CT at 4 hours were 87.5%, 100%, 100%, and 93.7%, respectively. The receiver operating characteristic (ROC) curve showed the accuracy of 64 Cu-PSMA PET/ CT in LN staging was characterized by an area under the curve of 0.938. In addition, there was a positive correlation between the 4-hour SUV max and Gleason score, index, and cumulative tumor volume. These preliminary studies indicated that 64 Cu-PSMA-617 PET/CT had high potential in the diagnosis and LN staging of patients with PCa, but further extensive clinical studies are still needed. 64 Cu-PSMA-617 is a novel radiotracer for tumor imaging not only in PCa but also expressed in many solid tumor angiogenic systems, such as gastric cancer and colon cancer. 79 The specificity of 64 Cu-PSMA-617 is confirmed by cell uptake experiments in PSMA(þ) LNCaP cells as well as PSMA(À) PC-3 and gastric adenocarcinoma BGC-823 cells. 80 
Other Applications
In the past period of time, nanodevices and nanoparticles were used in biomedical research to investigate improved diagnostic and therapeutic agents.
14 When nanoparticles are linked to tumor targeting ligands, such as antibodies, proteins, peptides, or other biologically relevant small molecules, they can be used to target tumor antigens (biomarkers) as well as tumor vasculatures with high affinity and specificity. 81 The studies assessed the use of 64 Cu-labeled DOTAalendronate for PET imaging in normal or tumor-bearing aged, female, retired breeder Sprague-Dawley rats. 82 PET images showed excellent contrast between mammary microcalcifications and surrounding soft tissues. The study indicated that different types of tumors had significantly different 64 Cu-DOTA-alendronate uptakes, the radioactivity uptake in malignant tumors was higher than that in benign and normal tissues, and these variations in uptake (and resultant PET image intensity) were inversely proportional to the radiopacity of these tumor types on traditional mammograms. At the same time, the dosimetric analysis demonstrated a 64 Cu effective dose within the acceptable range for clinical PET imaging agents and the potential for translation into patients. 64 Cu has an intermediate half-life of 12.7 hours and unique decay profile, making it a favorable option for radiolabeling peptides, small molecules, and large biomolecules, such as antibodies and nanoparticles for PET imaging and radionuclide therapy. The versatility of copper and its compounds makes it a powerful advantage in the development of new pharmaceuticals. This is conducive to the greater role of nuclear medicine imaging in the diagnosis and treatment of diseases and will have a profound impact on the formation of new medical models and human health. However, studies reported that 64 Cu-TATE/ 64 Cu-DOTA was instable in vivo, and 64 Cu may dissociate from the TETA or DOTA chelator. Therefore, significant research has been devoted to the development of ligands that can stably chelate 64 Cu.
Conclusions
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